JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Guardant Health Inc

Fermé

SecteurSoins de santé

89.17 1.4

Résumé

Variation du prix de l'action

24h

Actuel

Min

85.56

Max

90.78

Chiffres clés

By Trading Economics

Revenu

-36M

-128M

Ventes

16M

281M

BPA

-0.5

Marge bénéficiaire

-45.684

Employés

2,490

EBITDA

-37M

-119M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+46.73% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-1.7B

12B

Ouverture précédente

87.77

Clôture précédente

89.17

Sentiment de l'Actualité

By Acuity

50%

50%

186 / 348 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Guardant Health Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 avr. 2026, 19:19 UTC

Acquisitions, Fusions, Rachats

Intertek Group Rejects EQT's Revised Offer

24 avr. 2026, 23:37 UTC

Acquisitions, Fusions, Rachats

Scoring the Cook Era -- Barrons.com

24 avr. 2026, 20:51 UTC

Acquisitions, Fusions, Rachats

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 avr. 2026, 20:50 UTC

Market Talk
Principaux Événements d'Actualité

Financial Services Roundup: Market Talk

24 avr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 avr. 2026, 20:39 UTC

Acquisitions, Fusions, Rachats

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 avr. 2026, 20:09 UTC

Résultats

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 avr. 2026, 19:48 UTC

Market Talk
Principaux Événements d'Actualité

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 avr. 2026, 19:25 UTC

Acquisitions, Fusions, Rachats

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 avr. 2026, 19:25 UTC

Acquisitions, Fusions, Rachats

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 avr. 2026, 19:22 UTC

Résultats

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 avr. 2026, 19:06 UTC

Résultats

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 avr. 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 avr. 2026, 18:30 UTC

Acquisitions, Fusions, Rachats

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 avr. 2026, 18:28 UTC

Acquisitions, Fusions, Rachats

Intertek Rejects Revised EQT Offer

24 avr. 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 avr. 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 avr. 2026, 17:42 UTC

Résultats

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 avr. 2026, 17:28 UTC

Résultats

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 avr. 2026, 17:28 UTC

Market Talk

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 avr. 2026, 17:12 UTC

Market Talk

Global Equities Roundup: Market Talk

24 avr. 2026, 17:11 UTC

Market Talk

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 avr. 2026, 17:09 UTC

Market Talk
Résultats

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 avr. 2026, 17:09 UTC

Acquisitions, Fusions, Rachats

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 avr. 2026, 17:06 UTC

Résultats
Acquisitions, Fusions, Rachats

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 avr. 2026, 16:51 UTC

Résultats
Acquisitions, Fusions, Rachats

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 avr. 2026, 16:20 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

24 avr. 2026, 16:20 UTC

Market Talk
Principaux Événements d'Actualité

Financial Services Roundup: Market Talk

24 avr. 2026, 16:20 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

24 avr. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Comparaison

Variation de prix

Guardant Health Inc prévision

Objectif de Prix

By TipRanks

46.73% hausse

Prévisions sur 12 Mois

Moyen 128.93 USD  46.73%

Haut 175 USD

Bas 86.72 USD

Basé sur 18 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

18 ratings

17

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

38.86 / 47.41Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

186 / 348Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat